Dr. Roger Macklis, a radiation oncologist at Cleveland Clinic, has for years agitated for an expanded role for radioimmunotherapy -- not just Zevalin, but also for its competitor Bexxar.
Cleveland Clinic oncologist Roger Macklis has for some time supported the owners of the underachieving drug Zevalin as a fresh way to treat lymphatic cancer: Piggyback that drug on other chemotherapy drugs to increase the effectiveness of initial treatments. A regulatory change could happen in July that fulfills Macklis' mission for greater use of drugs like Zevalin.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.